Zepbound® (tirzepatide) was FDA-approved in November 2023 for chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity. Same active ingredient as Mounjaro®, different FDA-approved indication.
Zepbound® (tirzepatide) was FDA-approved in November 2023 for chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity. Same active ingredient as Mounjaro®, different FDA-approved indication.
Manufacturer / source: Eli Lilly and Company
For tirzepatide forms head-to-head, see comparison page. For trial data, see clinical research.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000